An Israeli bio pharmaceutical company said that it has the resources to produce ZMapp – the drug that can potentially cure Ebola.

The death toll from the Ebola epidemic has climbed above 2,000, the World Health Organisation (WHO) said Friday, as it voiced hopes a vaccine could be available in November.

However, supplies of experimental medicines — including the prototype drug ZMapp — are limited, and “will not be sufficient for several months to come,” the World Health Organisation (WHO) warned Friday.

Protalix, an Israeli bio pharmaceutical company, said that it has the resources to produce the coveted ZMapp, which has recently run out, Israeli site The Times of Israel, citing Channel 2 TV‘s report, said Sunday.

In an interview with Channel 2, Dr. Yossi Shaaltiel, the executive vice president of research and development at Protalix, said: “Today our production capacity exceeds our needs, and we would certainly be happy to have the company producing the Ebola drug have us produce the drug for them. We would know how to do it effectively, in large quantities, and in a relatively short period of time.”

According to the UN health organization’s data, the deadly Ebola virus has claimed 2,097 lives out of 3,944 people infected in Liberia, Guinea and Sierra Leone, since emerging last December.

Click here for the full article.

Source: i24news